HRP20140720T1 - Spoj derivat cikloheksana - Google Patents
Spoj derivat cikloheksana Download PDFInfo
- Publication number
- HRP20140720T1 HRP20140720T1 HRP20140720AT HRP20140720T HRP20140720T1 HR P20140720 T1 HRP20140720 T1 HR P20140720T1 HR P20140720A T HRP20140720A T HR P20140720AT HR P20140720 T HRP20140720 T HR P20140720T HR P20140720 T1 HRP20140720 T1 HR P20140720T1
- Authority
- HR
- Croatia
- Prior art keywords
- groups
- methyl
- group
- acceptable salt
- pharmacologically acceptable
- Prior art date
Links
- -1 Cyclohexane derivative compound Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 42
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 38
- 150000001875 compounds Chemical class 0.000 claims 28
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 19
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 19
- 125000005842 heteroatom Chemical group 0.000 claims 19
- 229910052757 nitrogen Inorganic materials 0.000 claims 19
- 229910052760 oxygen Inorganic materials 0.000 claims 19
- 239000001301 oxygen Substances 0.000 claims 19
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 18
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 15
- 229910052717 sulfur Inorganic materials 0.000 claims 12
- 239000011593 sulfur Substances 0.000 claims 12
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 11
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 7
- 239000005864 Sulphur Substances 0.000 claims 7
- 125000001931 aliphatic group Chemical group 0.000 claims 7
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 4
- ADYMZCRGMPSHGY-DPPGTGKWSA-N C[C@@H]1NCCN(CC(C(C)=C2)=CC=C2N(C)C([C@H](CC2)CC[C@@H]2OC2=CC=CC(CCNC(O)=O)=C2)=O)C1 Chemical compound C[C@@H]1NCCN(CC(C(C)=C2)=CC=C2N(C)C([C@H](CC2)CC[C@@H]2OC2=CC=CC(CCNC(O)=O)=C2)=O)C1 ADYMZCRGMPSHGY-DPPGTGKWSA-N 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 230000000069 prophylactic effect Effects 0.000 claims 4
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 3
- 206010010774 Constipation Diseases 0.000 claims 3
- 125000004442 acylamino group Chemical group 0.000 claims 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- VXJQBPNTTCOPBC-MPYJOUPCSA-N C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)[C@@H]2CC[C@H](CC2)NC=2C=C(CCOC(=O)N(C)C)C=CC=2)C=C1C Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)[C@@H]2CC[C@H](CC2)NC=2C=C(CCOC(=O)N(C)C)C=CC=2)C=C1C VXJQBPNTTCOPBC-MPYJOUPCSA-N 0.000 claims 2
- LOXYJSNRUXALAY-MPYJOUPCSA-N C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)[C@@H]2CC[C@H](CC2)NC=2C=C(COCC(C)(C)O)C=CC=2)C=C1C Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)[C@@H]2CC[C@H](CC2)NC=2C=C(COCC(C)(C)O)C=CC=2)C=C1C LOXYJSNRUXALAY-MPYJOUPCSA-N 0.000 claims 2
- XCVUPJBVKKACQB-KJOQGJGQSA-N C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)[C@@H]2CC[C@H](CC2)OC=2C=C(CO)C=CC=2)C=C1C Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)[C@@H]2CC[C@H](CC2)OC=2C=C(CO)C=CC=2)C=C1C XCVUPJBVKKACQB-KJOQGJGQSA-N 0.000 claims 2
- UQLOMSWYQXPSQD-MIUCGUHXSA-N C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)[C@@H]2CC[C@H](CC2)OC=2C=C(COCC(C)(C)O)C=CC=2)C=C1C Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)[C@@H]2CC[C@H](CC2)OC=2C=C(COCC(C)(C)O)C=CC=2)C=C1C UQLOMSWYQXPSQD-MIUCGUHXSA-N 0.000 claims 2
- FHXUQXPSWFJXLH-WATLYSKOSA-N C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)[C@@H]2CC[C@H](CC2)OC=2C=C(N=CC=2)C#N)C=C1C Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)[C@@H]2CC[C@H](CC2)OC=2C=C(N=CC=2)C#N)C=C1C FHXUQXPSWFJXLH-WATLYSKOSA-N 0.000 claims 2
- UNZQIZYYDGBZSR-MIUCGUHXSA-N CC(C)NC(=O)CC1=CC=CC(O[C@@H]2CC[C@H](CC2)C(=O)N(C)C=2C=C(C)C(CN3C[C@H](C)NCC3)=CC=2)=C1 Chemical compound CC(C)NC(=O)CC1=CC=CC(O[C@@H]2CC[C@H](CC2)C(=O)N(C)C=2C=C(C)C(CN3C[C@H](C)NCC3)=CC=2)=C1 UNZQIZYYDGBZSR-MIUCGUHXSA-N 0.000 claims 2
- JFIZDEQBSNNYDV-RMDSEJHCSA-N CNC(=O)OCCC1=CC=CC(N[C@@H]2CC[C@H](CC2)C(=O)N(C)C=2C=C(C)C(CN3C[C@H](C)NCC3)=CC=2)=C1 Chemical compound CNC(=O)OCCC1=CC=CC(N[C@@H]2CC[C@H](CC2)C(=O)N(C)C=2C=C(C)C(CN3C[C@H](C)NCC3)=CC=2)=C1 JFIZDEQBSNNYDV-RMDSEJHCSA-N 0.000 claims 2
- 206010051153 Diabetic gastroparesis Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 claims 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- MZERJFASZZIMKK-KJOQGJGQSA-N C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)[C@@H]2CC[C@H](CC2)OC=2C=C(CC(O)=O)C=CC=2)C=C1C Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)[C@@H]2CC[C@H](CC2)OC=2C=C(CC(O)=O)C=CC=2)C=C1C MZERJFASZZIMKK-KJOQGJGQSA-N 0.000 claims 1
- XACOFZQZNDCQBY-DPPGTGKWSA-N C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)[C@@H]2CC[C@H](CC2)OC=2C=C(CCO)C=CC=2)C=C1C Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)[C@@H]2CC[C@H](CC2)OC=2C=C(CCO)C=CC=2)C=C1C XACOFZQZNDCQBY-DPPGTGKWSA-N 0.000 claims 1
- XSRJNPUCQNDPRR-PTLVVNQVSA-N C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)[C@@H]2CC[C@H](CC2)OC=2C=CC(F)=CC=2)C=C1 Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)[C@@H]2CC[C@H](CC2)OC=2C=CC(F)=CC=2)C=C1 XSRJNPUCQNDPRR-PTLVVNQVSA-N 0.000 claims 1
- GJHNTJDKWVLGHO-WATLYSKOSA-N C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)[C@@H]2CC[C@H](CC2)OC=2C=CC(F)=CC=2)C=C1C Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)[C@@H]2CC[C@H](CC2)OC=2C=CC(F)=CC=2)C=C1C GJHNTJDKWVLGHO-WATLYSKOSA-N 0.000 claims 1
- FLVYLBRKKSWSEE-SKPFHBQLSA-N C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)[C@@H]2CC[C@H](CC2)OC=2N=CC(F)=CC=2)C=C1C Chemical compound C1CN[C@@H](C)CN1CC1=CC=C(N(C)C(=O)[C@@H]2CC[C@H](CC2)OC=2N=CC(F)=CC=2)C=C1C FLVYLBRKKSWSEE-SKPFHBQLSA-N 0.000 claims 1
- AORCPSGLFOPGKA-MIUCGUHXSA-N CC(C)OC(=O)CC1=CC=CC(O[C@@H]2CC[C@H](CC2)C(=O)N(C)C=2C=C(C)C(CN3C[C@H](C)NCC3)=CC=2)=C1 Chemical compound CC(C)OC(=O)CC1=CC=CC(O[C@@H]2CC[C@H](CC2)C(=O)N(C)C=2C=C(C)C(CN3C[C@H](C)NCC3)=CC=2)=C1 AORCPSGLFOPGKA-MIUCGUHXSA-N 0.000 claims 1
- YFJWAFLCNBBZGC-AGJHTDJMSA-N CCOC(=O)CC1=CC=CC(O[C@@H]2CC[C@H](CC2)C(=O)N(C)C=2C=C(C)C(CN3C[C@H](C)NCC3)=CC=2)=C1 Chemical compound CCOC(=O)CC1=CC=CC(O[C@@H]2CC[C@H](CC2)C(=O)N(C)C=2C=C(C)C(CN3C[C@H](C)NCC3)=CC=2)=C1 YFJWAFLCNBBZGC-AGJHTDJMSA-N 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical group F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 101001132878 Homo sapiens Motilin receptor Proteins 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- 206010021333 Ileus paralytic Diseases 0.000 claims 1
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 102100033818 Motilin receptor Human genes 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 208000030053 Opioid-Induced Constipation Diseases 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940124413 agent for gastroesophageal reflux disease Drugs 0.000 claims 1
- 229940124415 agent for irritable bowel syndrome Drugs 0.000 claims 1
- 125000000033 alkoxyamino group Chemical group 0.000 claims 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 229940072107 ascorbate Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 150000001509 aspartic acid derivatives Chemical class 0.000 claims 1
- 229940077388 benzenesulfonate Drugs 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 1
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 150000002332 glycine derivatives Chemical class 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 201000007620 paralytic ileus Diseases 0.000 claims 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Claims (32)
1. Spoj predstavljen slijedećom općom formulom (I) ili njegova farmakološki prihvatljiva sol:
[image]
u kojem A predstavlja fenilen grupu (fenilen grupa može biti izborno supstituirana sa 1 do 3 grupe izabrane od C1-C3 alkil grupe, C1-C3 alkoksi grupe, i atoma halogena); B predstavlja 4- do 10-članu heterocikličnu grupu koja sadrži 1 do 4 heteroatoma koji mogu biti isti ili različiti i izabrani su od dušika, kisika, i sumpora (heterociklična grupa može biti izborno supstituirana sa 1 do 5 grupa izabranih od grupe supstituenta α), C6-C10 aril grupu (aril grupa može biti izborno supstituirana sa 1 do 5 grupa izabranih od grupe supstituenta α), ili C3-C10 cikloalkil grupu (cikloalkil grupa može biti izborno supstituirana sa 1 do 5 grupa izabranih od grupe supstituenta α); R1 predstavlja atom vodika ili C1-C3 alkil grupu; R2 predstavlja atom vodika ili C1-C3 alkil grupu; R3 predstavlja C1-C6 alkil grupu, C3-C10 cikloalkil grupu, C1-C3 alkoksi C1-C3 alkil grupu, ili C1-C3 hidroksialkil grupu; R4 predstavlja atom vodika, C1-C6 alkil grupu ili atom halogena; n predstavlja cijeli broj od 1 do 4; X predstavlja metilen, -O-, -NH-, -N(C1-C3 alkil)-, -C(=O)-, -S-, -S(O)-, -S(O2)- ili jednogubu vezu;
i grupa supstituent α sastoji se od atoma halogena, C1-C6 alkil grupe {alkil grupa može biti izborno supstituirana sa 1 do 3 grupe izabrane od C1-C6 alifatične acil grupe, karboksil grupe, C1-C6 alkoksikarbonil grupe, aminokarbonil grupe (aminokarbonil grupa može biti izborno supstituirana sa 1 ili 2 grupe izabrane od C1-C6 alkil grupe, C1-C6 haloalkil grupe, i C1-C6 alkoksi C1-C6 alkil grupe), karbamido grupe izborno supstituirane sa jednom ili tri C1-C6 alkil grupe, C1-C6 alifatične acilamino grupe koja može biti izborno supstituirana sa C1-C6 alkoksi grupom, C1-C6 alifatične acil C1-C6 alkilamino grupe, amidoksi grupe koja može biti izvorno supstituirana sa jednom ili dvije C1-C6 alkil grupe, C1-C6 alkilsulfonil grupe, 4- do 10-člane heterociklične grupe koja sadrži 1 do 4 heteroatoma koji mogu biti isti ili različiti i izabrani su od dušika, kisika i sumpora, i 4- do 10-člane heterociklične karbonil grupe koja sadrži 1 do 4 heteroatoma koji mogu biti isti ili različiti i izabrani su od dušika, kisika i sumpora}, C3-C10 cikloalkil grupe (cikloalkil grupa može biti izborno supstituirana sa 1 do 3 grupe izabrane od karboksil grupe, C1-C6 alkoksikarbonil grupe i 4- do 10-člane heterociklične grupe koja sadrži 1 do 4 heteroatoma koji mogu biti isti ili različiti i izabrani su od dušika, kisika i sumpora), C1-C6 haloalkil grupe (haloalkil grupa može biti izborno supstituirana sa 1 do 3 grupe izabrane od karboksil grupe, C1-C6 alkoksikarbonil grupe i 4- do 10-člane heterociklične grupe koja sadrži 1 do 4 heteroatoma koji mogu biti isti ili različiti i izabrani su od dušika, kisika i sumpora), C1-C6 hidroksialkil grupe (hidroksialkil grupa može biti izborno supstituirana sa 1 do 3 grupe izabrane od karboksil grupe, C1-C6 alkoksikarbonil grupe i 4- do 10-člane heterociklične grupe koja sadrži 1 do 4 heteroatoma koji mogu biti isti ili različiti i izabrani su od dušika, kisika i sumpora), C1-C6 alkoksi C1-C6 alkil grupe (alkoksialkil grupa može biti izborno supstituirana sa 1 do 3 grupe izabrane od hidroksi grupe, C1-C6 alkoksi grupe, C1-C6 hidroksialkil grupe, aminokarbonil grupe koja može biti izborno supstituirana sa C1-C6 alkil, karboksil grupom, C1-C6 alkoksikarbonil grupom, i 4- do 10-članom heterocikličnom grupom koja sadrži 1 do 4 heteroatoma koji mogu biti isti ili različiti i izabrani su od dušika, kisika i sumpora), 4- do 10-člane heterociklične grupe koja sadrži 1 do 4 heteroatoma koji mogu biti isti ili različiti i izabrani su od dušika, kisika i sumpora, C1-C6 aminoalkil grupe, C1-C6 alkoksi grupe, C1-C6 haloalkoksi grupe, C1-C6 hidroksialkoksi grupe, C6-C10 ariloksi grupe, C1-C6 alkiltio grupe, karboksil grupe, C1-C6 alkoksikarbonil grupe, hidroksi grupe, C1-C6 alifatične acil grupe, amino grupe, C1-C6 alkilamino grupe, C3-C10 cikloalkilamino grupe, C1-C6 dialkilamino grupe, C1-C6 alkoksiamino grupe, C1-C6 alifatične acilamino grupe, cijano grupe, nitro grupe, C1-C6 alkilsulfonil grupe, C1-C6 dialkilaminosulfonil grupe i C6-C10 aril grupe.
2. Spoj ili njegova farmakološki prihvatljiva sol prema patentnom zahtjevu 1, naznačen time što A je fenilen grupa koja može biti izborno supstituirana sa jednom do tri C1-C3 alkil grupe.
3. Spoj ili njegova farmakološki prihvatljiva sol prema patentnom zahtjevu 1 ili 2, naznačen time što B je 4- do 10-člana heterociklična grupa koja sadrži 1 do 4 heteroatoma koji mogu biti isti ili različiti i izabrani su od dušika, kisika i sumpora (heterociklična grupa može biti izborno supstituirana sa 1 do 5 grupa izabranih od grupe supstituenta α) ili C6-C10 aril grupa (aril grupa može biti izborno supstituirana sa 1 do 5 grupa izabranih od grupe supstituenta α).
4. Spoj ili njegova farmakološki prihvatljiva sol prema patentnom zahtjevu 1 ili 2, naznačen time što B je piridil grupa koja može biti izborno susptituirana sa 1 do 5 grupa izabranih od grupe supstituenta α ili fenil grupe koja može biti izborno supstituirana sa 1 do 5 grupa izabranih od grupe supstituenta α.
5. Spoj ili njegova farmakološki prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time što R1 je C1-C3 alkil grupa.
6. Spoj ili njegova farmakološki prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time što R2 je atom vodika.
7. Spoj ili njegova farmakološki prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time što R3 je C1-C3 alkil grupa.
8. Spoj ili njegova farmakološki prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što R4 je atom vodika.
9. Spoj ili njegova farmakološki prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time što X je –O ili -NH-.
10. Spoj ili njegova farmakološki prihvatljiva sol prema patentnom zahtjevu 1, predstavljen slijedećom općom formulom (IA) ili njegova farmakološki prihvatljiva sol:
[image]
u kojim B, R1, R2, R3, R4, X, i n su kao što su definirani u patentnom zahtjevu 1.
11. Spoj ili njegova farmakološki prihvatljiva sol prema patentnom zahtjevu 1, predstavljen slijedećom općom formulom (IB) ili njegova farmakološki prihvatljiva sol:
[image]
gdje R1 predstavlja atom vodika ili C1-C3 alkil grupu; R5 predstavlja grupu izabranu od grupe supstituenta α; i grupa supstituent α je kao što je definirana u patentnom zahtjevu 1.
12. Spoj ili njegova farmakološki prihvatljiva sol prema patentnom zahtjevu 11, naznačen time što R1 je metil grupa.
13. Spoj ili njegova farmakološki prihvatljiva sol prema patentnom zahtjevu 11 ili 12, naznačen time što R5 je C1-C6 alkil grupa (alkil grupa je izborno supstituirana sa 1 do 3 grupe izabrane od C1-C6 alifatične acil grupe, karboksil grupe, C1-C6 alkoksikarbonil grupe, aminokarbonil grupe (aminokarbonil grupa je izborno supstituirana sa 1 ili 2 grupe izabrane od C1-C6 alkil grupe, C1-C6 haloalkil grupe, i C1-C6 alkoksi C1-C6 alkil grupe), karbamido grupe izborno supstituirane sa jednom do tri C1-C6 alkil grupe, C1-C6 alifatične acilamino grupe izborno supstituirane sa C1-C6 alkoksi grupom, C1-C6 alifatične acil C1-C6 alkilamino grupe, amidoksi grupe izborno supstituirane sa jednom ili dvije C1-C6 alkil grupe, C1-C6 alkilsulfonil grupe, 4- do 10-člane heterociklične grupe koja sadrži 1 do 4 heteroatoma koji mogu biti isti ili različiti i izabrani su od dušika, kisika i sumpora, i 4- do 10-člane heterociklične karbonil grupe koja sadrži 1 do 4 heteroatoma koji mogu biti isti ili različiti i izabrani su od dušika, kisika i sumpora}, C1-C6 hidroksialkil grupe (hidroksialkil grupe koja je izborno supstituirana sa 1 do 3 grupe izabrane od karboksil grupe, C1-C6 alkoksikarbonil grupe i 4- do 10-člane heterociklične grupe koja sadrži 1 do 4 heteroatoma koji mogu biti isti ili različiti i izabrani su od dušika, kisika i sumpora), ili C1-C6 alkoksi C1-C6 alkil grupe (alkoksialkil grupa je izborno supstituirana sa 1 do 3 grupe izabrane od hidroksi grupe, C1-C6 alkoksi grupe, C1-C6 hidroksialkil grupe, aminokarbonil grupe izborno supstituirane sa C1-C6 alkil, karboksil grupe, C1-C6 alkoksikarbonil grupe i 4- do 10-člane heterociklične grupe koja sadrži 1 do 4 heteroatoma koji mogu biti isti ili različiti i izabrani su od dušika, kisika i sumpora).
14. Spoj ili njegova farmakološki prihvatljiva sol prema patentnom zahtjevu 1, naznačen time što se grupa supstituent α sastoji od atoma halogena, C1-C6 alkil grupe (alkil grupa je izborno supstituirana sa 1 do 3 grupe izabrane od karboksil grupe, C1-C6 alkoksikarbonil grupe i 4- do 10-člane heterociklične grupe koja sadrži 1 do 4 heteroatoma koji mogu biti isti ili različiti i izabrani su od dušika, kisika i sumpora), C3-C10 cikloalkil grupe (cikloalkil grupa je izborno supstituirana sa 1 do 3 grupe izabrane od karboksil grupe, C1-C6 alkoksikarbonil grupe, i 4- do 10-člane heterociklične grupe koja sadrži 1 do 4 heteroatoma koji mogu biti isti ili različiti i izabrani su od dušika, kisika i sumpora), C1-C6 haloalkil grupe (haloalkil grupa je izborno supstituirana sa 1 do 3 grupe izabrane od karboksil grupe, C1-C6 alkoksikarbonil grupe, i 4- do 10-člane heterociklične grupe koja sadrži 1 do 4 heteroatoma koji mogu biti isti ili različiti i izabrani su od dušika, kisika i sumpora), C1-C6 hidroksialkil grupe (hidroksialkil grupa je izborno supstituirana sa 1 do 3 grupe izabrane od karboksil grupe, C1-C6 alkoksikarbonil grupe, i 4- do 10-člane heterociklične grupe koja sadrži 1 do 4 heteroatoma koji mogu biti isti ili različiti i izabrani su od dušika, kisika i sumpora), C1-C6 alkoksi C1-C6 alkil grupe (alkoksialkil grupa je izborno supstituirana sa 1 do 3 grupe izabrane od karboksil grupe, C1-C6 alkoksikarbonil grupe i 4- do 10-člane heterociklične grupe koja sadrži 1 do 4 heteroatoma koji mogu biti isti ili različiti i izabrani su od dušika, kisika i sumpora), 4- do 10-člane heterociklične grupe koja sadrži 1 do 4 heteroatoma koji mogu biti isti ili različiti i izabrani su od dušika, kisika i sumpora, C1-C6 aminoalkil grupe, C1-C6 alkoksi grupe, C1-C6 haloalkoksi grupe, C1-C6 hidroksialkoksi grupe, C6-C10 ariloksi grupe, C1-C6 alkiltio grupe, karboksil grupe, C1-C6 alkoksikarbonil grupe, hidroksi grupe, C1-C6 alifatične acil grupe, amino grupe, C1-C6 alkilamino grupe, C3-C10 cikloalkilamino grupe, C1-C6 dialkilamino grupe, C1-C6 alkoksiamino grupe, C1-C6 alifatične acilamino grupe, cijano grupe, nitro grupe, C1-C6 alkilsulfonil grupe, C1-C6 dialkilaminosulfonil grupe i C6-C10 aril grupe.
15. Spoj ili njegova farmakološki prihvatljiva sol prema patentnom zahtjevu 1, koji je:
trans-4-(4-fluorofenoksi)-N-metil-N-(4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)cikloheksan-karboksamid,
trans-4-(4-fluorofenoksi)-N-metil-N-(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil) cikloheksankarboksamid,
trans-4-[(5-fluoropiridin-2-il)oksi]-N-metil-N-(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)cikloheksankarboksamid,
trans-4-[3-(hidroksimetil)fenoksi]-N-metil-N-(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)cikloheksankarboksamid,
trans-4-[3-(2-hidroksietil)fenoksi]-N-metil-N-(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)cikloheksankarboksamid,
etil [3-({trans-4-[metil(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)karbamoil]ciklo-heksil}oksi)fenil]acetat,
[3-({trans-4-[metil(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)karbamoil]cikloheksil}oksi)fenil]octena kiselina,
izopropil [3-({trans-4-[metil(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)karbamoil]cikloheksil}oksi)fenil]acetat,
ili njegova farmakološki prihvatljiva sol.
16. Spoj ili njegova farmakološki prihvatljiva sol prema patentnom zahtjevu 1, koji je:
trans-4-{3-[(2-hidroksi-2-metilpropoksi)metil]fenoksi}-N-metil-N-(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)cikloheksankarboksamid,
trans-4-({3-[(2-hidroksi-2-metilpropoksi)metil]fenil}amino)-N-metil-N-(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)cikloheksankarboksamid,
3-({trans-4-[metil(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)karbamoil]cikloheksil}oksi)benzilmetilkarbamat,
2-[3-({trans-4-[metil(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)karbamoil]cikloheksil}oksi)fenil]etilkarbamat,
2-[3-({trans-4-[metil(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)karbamoil]cikloheksil}amino)fenil]etilmetilkarbamat,
2-[3-({trans-4-[metil(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)karbamoil]cikloheksil}amino)fenil]etildimetilkarbamat,
trans-4-{3-[2-(izopropilamino)-2-oksoetil]fenoksi}-N-metil-N-(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)cikloheksankarboksamid,
trans-4-[(2-cijanopiridin-4-il)oksi]-N-metil-N-(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)cikloheksankarboksamid,
ili njegova farmakološki prihvatljiva sol.
17. Spoj ili njegova farmakološki prihvatljiva sol prema patentnom zahtjevu 1, koji je:
trans-4-[3-(hidroksimetil)fenoksi]-N-metil-N-(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)cikloheksankarboksamid
ili njegova farmakološki prihvatljiva sol.
18. Spoj ili njegova farmakološki prihvatljiva sol prema patentnom zahtjevu 1, koji je:
trans-4-[(2-cijanopiridin-4-il)oksi]-N-metil-N-(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)cikloheksankarboksamid
ili njegova farmakološki prihvatljiva sol.
19. Spoj ili njegova farmakološki prihvatljiva sol prema patentnom zahtjevu 1, koji je:
trans-4-{3-[2-(izopropilamino)-2-oksoetil]fenoksi}-N-metil-N-(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)cikloheksankarboksamid
ili njegova farmakološki prihvatljiva sol.
20. Spoj ili njegova farmakološki prihvatljiva sol prema patentnom zahtjevu 1, koji je:
trans-4-{3-[(2-hidroksi-2-metilpropoksi)metil]fenoksi}-N-metil-N-(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)cikloheksankarboksamid
ili njegova farmakološki prihvatljiva sol.
21. Spoj ili njegova farmakološki prihvatljiva sol prema patentnom zahtjevu 1, koji je:
trans-4-({3-[(2-hidroksi-2-metilpropoksi)metil]fenil}amino)-N-metil-N-(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)cikloheksankarboksamid
ili njegova farmakološki prihvatljiva sol.
22. Spoj ili njegova farmakološki prihvatljiva sol prema patentnom zahtjevu 1, koji je:
3-({trans-4-[metil(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)karbamoil]cikloheksil}oksi)benzilmetilkarbamat
ili njegova farmakološki prihvatljiva sol.
23. Spoj ili njegova farmakološki prihvatljiva sol prema patentnom zahtjevu 1, koji je:
2-[3-({trans-4-[metil(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)karbamoil]cikloheksil}oksi)fenil]etilkarbamat
ili njegova farmakološki prihvatljiva sol.
24. Spoj ili njegova farmakološki prihvatljiva sol prema patentnom zahtjevu 1, koji je:
2-[3-({trans-4-[metil(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)karbamoil]cikloheksil}amino)fenil]etilmetilkarbamat
ili njegova farmakološki prihvatljiva sol.
25. Spoj ili njegova farmakološki prihvatljiva sol prema patentnom zahtjevu 1, koji je:
2-[3-({trans-4-[metil(3-metil-4-{[(3S)-3-metilpiperazin-1-il]metil}fenil)karbamoil]cikloheksil}amino)fenil]etil dimetilkarbamat
ili njegova farmakološki prihvatljiva sol.
26. Spoj ili njegova farmakološki prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 25, naznačen time što je farmakološki prihvatljiva sol hidrofluorid, hidroklorid, hidrobromid, hidrojodid, nitrat, perklorat, sulfat, fosfat, metansulfonat, trifluorometansulfonat, etansulfonat, benzensulfonat, p-toluensulfonat, acetat, malat, fumarat, sukcinat, citrat, askorbat, tartarat, oksalat, maleat, sol glicina, sol lizina, sol arginina, sol ornitina, sol glutaminske kiseline ili sol asparaginske kiseline.
27. Lijek koji sadrži spoj ili njegovu farmakološki sol prema bilo kojem od patentnih zahtjeva 1 do 26 kao aktivni sastojak.
28. Lijek prema patentnom zahtjevu 27, za uporabu u prevenciji ili liječenju bolesti povezane sa GPR38.
29. Lijek prema patentnom zahtjevu 27, za uporabu kao terapeutsko ili profilaktičko sredstvo za gastrointestinalni poremećaj povezan sa hipomotilitetom.
30. Lijek prema patentnom zahtjevu 27, za uporabu kao terapeutsko ili profilaktičko sredstvo za sindrom iritabilnog crijeva sa konstipacijom, dijabetičku gastroparezu ili konstipaciju.
31. Lijek prema patentnom zahtjevu 27, za uporabu kao terapeutsko ili profilaktičko sredstvo za gastroezofagealnu refluksnu bolest, funkcionalnu dispepsiju, sindrom iritabilnog crijeva, dijabetičku gastroparezu, konstipaciju, opioidom-induciranu disfunkciju crijeva, paralitički ileus ili postoperativnu gastrointestinalnu paralizu.
32. Uporaba spoja ili njegove farmakološki prihvatljive soli prema bilo kojem od patentnih zahtjeva 1 do 26 za proizvodnju profilaktičkog ili terapeutskog sredstva za gastrointestinalni poremećaj povezan sa hipomotilitetom.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010215403 | 2010-09-27 | ||
PCT/JP2011/071830 WO2012043445A1 (ja) | 2010-09-27 | 2011-09-26 | シクロヘキサン誘導体化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20140720T1 true HRP20140720T1 (hr) | 2014-08-29 |
Family
ID=45892891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20140720AT HRP20140720T1 (hr) | 2010-09-27 | 2014-07-25 | Spoj derivat cikloheksana |
Country Status (29)
Country | Link |
---|---|
US (3) | US8710060B2 (hr) |
EP (1) | EP2623492B1 (hr) |
JP (1) | JP5753179B2 (hr) |
KR (1) | KR20130109124A (hr) |
CN (1) | CN103108866B (hr) |
AU (1) | AU2011309212B2 (hr) |
BR (1) | BR112013007145A2 (hr) |
CA (1) | CA2812898C (hr) |
CO (1) | CO6690804A2 (hr) |
CY (1) | CY1115450T1 (hr) |
DK (1) | DK2623492T3 (hr) |
ES (1) | ES2478518T3 (hr) |
HK (1) | HK1185081A1 (hr) |
HR (1) | HRP20140720T1 (hr) |
IL (1) | IL225440A (hr) |
IN (1) | IN2013MN00506A (hr) |
MX (1) | MX2013003219A (hr) |
MY (1) | MY157542A (hr) |
NZ (1) | NZ609596A (hr) |
PL (1) | PL2623492T3 (hr) |
PT (1) | PT2623492E (hr) |
RS (1) | RS53447B (hr) |
RU (1) | RU2013119603A (hr) |
SG (1) | SG188415A1 (hr) |
SI (1) | SI2623492T1 (hr) |
SM (1) | SMT201400109B (hr) |
TW (1) | TWI501953B (hr) |
WO (1) | WO2012043445A1 (hr) |
ZA (1) | ZA201301652B (hr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2013003219A (es) * | 2010-09-27 | 2013-06-18 | Daiichi Sankyo Co Ltd | Compuesto derivado de ciclohexano. |
US11318350B2 (en) | 2016-12-29 | 2022-05-03 | BioMech Sensor LLC | Systems and methods for real-time data quantification, acquisition, analysis, and feedback |
US10973439B2 (en) | 2016-12-29 | 2021-04-13 | BioMech Sensor LLC | Systems and methods for real-time data quantification, acquisition, analysis, and feedback |
US9773330B1 (en) | 2016-12-29 | 2017-09-26 | BioMech Sensor LLC | Systems and methods for real-time data quantification, acquisition, analysis, and feedback |
US10352962B2 (en) | 2016-12-29 | 2019-07-16 | BioMech Sensor LLC | Systems and methods for real-time data quantification, acquisition, analysis and feedback |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6511980B2 (en) * | 2000-05-05 | 2003-01-28 | Ortho Mcneil Pharmaceutical, Inc. | Substituted diamine derivatives useful as motilin antagonists |
US7262195B2 (en) * | 2003-09-17 | 2007-08-28 | Bristol-Myers Squibb Company | Compounds useful as motilin agonists and method |
GB0611907D0 (en) | 2006-06-15 | 2006-07-26 | Glaxo Group Ltd | Compounds |
GB0515381D0 (en) * | 2005-07-26 | 2005-08-31 | Glaxo Group Ltd | Compounds |
JP5028484B2 (ja) * | 2006-06-28 | 2012-09-19 | グラクソ グループ リミテッド | Gpr38受容体媒介疾患の治療に有用なピペラジニル誘導体 |
GB0612844D0 (en) * | 2006-06-28 | 2006-08-09 | Glaxo Group Ltd | Compounds |
GB0723317D0 (en) | 2007-11-28 | 2008-01-09 | Glaxo Group Ltd | Compounds |
MX2013003219A (es) * | 2010-09-27 | 2013-06-18 | Daiichi Sankyo Co Ltd | Compuesto derivado de ciclohexano. |
-
2011
- 2011-09-26 MX MX2013003219A patent/MX2013003219A/es active IP Right Grant
- 2011-09-26 PL PL11828999T patent/PL2623492T3/pl unknown
- 2011-09-26 ES ES11828999.0T patent/ES2478518T3/es active Active
- 2011-09-26 BR BR112013007145A patent/BR112013007145A2/pt not_active IP Right Cessation
- 2011-09-26 WO PCT/JP2011/071830 patent/WO2012043445A1/ja active Application Filing
- 2011-09-26 RS RS20140388A patent/RS53447B/en unknown
- 2011-09-26 KR KR1020137007448A patent/KR20130109124A/ko not_active Application Discontinuation
- 2011-09-26 IN IN506MUN2013 patent/IN2013MN00506A/en unknown
- 2011-09-26 NZ NZ609596A patent/NZ609596A/en not_active IP Right Cessation
- 2011-09-26 SI SI201130160T patent/SI2623492T1/sl unknown
- 2011-09-26 CN CN201180046082.8A patent/CN103108866B/zh not_active Expired - Fee Related
- 2011-09-26 SG SG2013016464A patent/SG188415A1/en unknown
- 2011-09-26 JP JP2012536427A patent/JP5753179B2/ja not_active Expired - Fee Related
- 2011-09-26 TW TW100134525A patent/TWI501953B/zh not_active IP Right Cessation
- 2011-09-26 EP EP11828999.0A patent/EP2623492B1/en active Active
- 2011-09-26 MY MYPI2013000841A patent/MY157542A/en unknown
- 2011-09-26 RU RU2013119603/04A patent/RU2013119603A/ru not_active Application Discontinuation
- 2011-09-26 CA CA2812898A patent/CA2812898C/en not_active Expired - Fee Related
- 2011-09-26 AU AU2011309212A patent/AU2011309212B2/en not_active Ceased
- 2011-09-26 PT PT118289990T patent/PT2623492E/pt unknown
- 2011-09-26 DK DK11828999.0T patent/DK2623492T3/da active
-
2013
- 2013-03-04 ZA ZA2013/01652A patent/ZA201301652B/en unknown
- 2013-03-21 IL IL225440A patent/IL225440A/en not_active IP Right Cessation
- 2013-03-26 US US13/850,981 patent/US8710060B2/en active Active
- 2013-04-19 CO CO13101069A patent/CO6690804A2/es active IP Right Grant
- 2013-11-11 HK HK13112618.2A patent/HK1185081A1/xx not_active IP Right Cessation
- 2013-12-27 US US14/142,479 patent/US9051255B2/en not_active Expired - Fee Related
- 2013-12-27 US US14/142,486 patent/US20140221392A1/en not_active Abandoned
-
2014
- 2014-07-25 HR HRP20140720AT patent/HRP20140720T1/hr unknown
- 2014-08-06 CY CY20141100614T patent/CY1115450T1/el unknown
- 2014-08-06 SM SM201400109T patent/SMT201400109B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20140720T1 (hr) | Spoj derivat cikloheksana | |
JP5586692B2 (ja) | アルカノイルアミノベンズアミドアニリンhdacインヒビター化合物 | |
ES2627221T3 (es) | Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso | |
CA2798360C (en) | Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same | |
ES2428746T3 (es) | Sales de adición de aminas que contienen grupos hidroxilo y/o carboxilo con derivados de ácidos aminonicotínicos como inhibidores de DHODH | |
NZ603198A (en) | Novel hydroxamic acid derivative | |
NZ582709A (en) | Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors | |
NO20071658L (no) | Alkil-pyridiner som 11-beta-inhibitorer for diabetes | |
WO2020160295A1 (en) | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | |
RU2009116670A (ru) | Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина | |
EP1302463A1 (en) | Medicine comprising dicyanopyridine derivative | |
CA2634676A1 (en) | Trisubstituted amine compounds as inhibitors of cholesteryl ester transfer protein cetp | |
HRP20120028T1 (hr) | 3-[(2-{[4-heksiloksikarbonilamino-imino-metil)fenilamino]-metil}-1-metil-1-h-benzimidazol-5-karbonil)-piridin-2-il-amino]propionska kiselina-etilester-metansulfonat-hemihidrat i njegova primjena kao lijeka | |
WO2009074749A2 (fr) | Dérives de nicotinamide. leur préparation et leur application en thérapeutique | |
WO2008078196A3 (en) | Substituted heteroaryl pyridopyrimidone derivatives | |
CA2476343A1 (en) | 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors | |
DK2993170T3 (da) | N-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamidderivater som aldh-2- hæmmere til behandling af afhængighed | |
AU2015230127A1 (en) | Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | |
FR2943669A1 (fr) | Derives de nicotinamide,leur preparation et leur application en therapeutique | |
HRP20151201T1 (hr) | Supstituirani derivati benzamida | |
HRP20151336T1 (hr) | Tetrahidroizokinolin-1-on derivat ili njegova sol | |
EP2651895A1 (en) | Oxime compounds as hdl-cholesterol raising agents | |
DK2439202T3 (en) | Inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1 | |
RU2015145989A (ru) | Замещенное биарильное соединение | |
Westaway et al. | Design and synthesis of 6-phenylnicotinamide derivatives as antagonists of TRPV1 |